Research

Transnational tobacco company interests in smokeless tobacco in Europe:Analysis of internal industry documents and contemporary industry materials


Reference:

Peeters, S. and Gilmore, A. B., 2013. Transnational tobacco company interests in smokeless tobacco in Europe:Analysis of internal industry documents and contemporary industry materials. PLoS Medicine, 10 (9), 1001506.

Related documents:

[img]
Preview
PDF (Published version) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (510kB) | Preview

    Official URL:

    http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001506

    Related URLs:

    Abstract

    Background: European Union (EU) legislation bans the sale of snus, a smokeless tobacco (SLT) which is considerably less harmful than smoking, in all EU countries other than Sweden. To inform the current review of this legislation, this paper aims to explore transnational tobacco company (TTC) interests in SLT and pure nicotine in Europe from the 1970s to the present, comparing them with TTCs' public claims of support for harm reduction. Methods and Results:Internal tobacco industry documents (in total 416 documents dating from 1971 to 2009), obtained via searching the online Legacy Tobacco Documents Library, were analysed using a hermeneutic approach. This library comprises documents obtained via litigation in the US and does not include documents from Imperial Tobacco, Japan Tobacco International, or Swedish Match. To help overcome this limitation and provide more recent data, we triangulated our documentary findings with contemporary documentation including TTC investor presentations. The analysis demonstrates that British American Tobacco explored SLT opportunities in Europe from 1971 driven by regulatory threats and health concerns, both likely to impact cigarette sales negatively, and the potential to create a new form of tobacco use among those no longer interested in taking up smoking. Young people were a key target. TTCs did not, however, make SLT investments until 2002, a time when EU cigarette volumes started declining, smoke-free legislation was being introduced, and public health became interested in harm reduction. All TTCs have now invested in snus (and recently in pure nicotine), yet both early and recent snus test markets appear to have failed, and little evidence was found in TTCs' corporate materials that snus is central to their business strategy. Conclusions:There is clear evidence that BAT's early interest in introducing SLT in Europe was based on the potential for creating an alternative form of tobacco use in light of declining cigarette sales and social restrictions on smoking, with young people a key target. We conclude that by investing in snus, and recently nicotine, TTCs have eliminated competition between cigarettes and lower-risk products, thus helping maintain the current market balance in favour of (highly profitable) cigarettes while ensuring TTCs' long-term future should cigarette sales decline further and profit margins be eroded.Please see later in the article for the Editors' Summary.

    Details

    Item Type Articles
    CreatorsPeeters, S.and Gilmore, A. B.
    DOI10.1371/journal.pmed.1001506
    Related URLs
    URLURL Type
    http://www.scopus.com/inward/record.url?scp=84884666800&partnerID=8YFLogxKUNSPECIFIED
    DepartmentsFaculty of Humanities & Social Sciences > Health
    Research CentresUK Centre for Tobacco Control Studies
    Publisher StatementGilmorePM2013_10_9.pdf: Copyright: 2013 Peeters, Gilmore. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    RefereedYes
    StatusPublished
    ID Code36856
    Additional InformationPMCID: PMC3769209

    Export

    Actions (login required)

    View Item

    Document Downloads

    More statistics for this item...